Pharmaceutical Excipients Market Size, Report By 2030

The global pharmaceutical excipients market size is projected to hit around US$ 12.61 billion by 2030, registering a CAGR of 5.9% from 2023 to 2030.

The demand for the oral formulations drugs has been witnessing a rapid increase from the past few years. This is attributable to the ease of consumption of these oral drug by the patient, especially children. Oral dosage formats usually require more amounts of excipients over other available drugs forms during the manufacturing process and is being promoted owing to the rising adoption of patient-centricity approaches by drug manufacturers globally.

Get the Sample Pages of Report@ https://www.precedenceresearch.com/sample/1761

For instance, approximately 50% of the patients across the world find it difficult to swallow conventional hard solid tablets. This has encouraged drug companies to come up with more innovative oral drug forms such as effervescent tablets, lozenges, instant drinks, orally disintegrating granules (ODGs), and chewable tablets. This is likely to offer immense opportunities for the increase in demand for excipients in the near future ultimately contributing in fueling the growth of the overall market in terms of value sales.

Regional Snapshot

Europe dominated the pharmaceutical excipient market share in the year 2020, the growing government initiatives for reducing the prices of the drugs along with the rising investments for the development of biologics as well as advanced dosage forms, is increasing the demand for new excipients and thereby contributing in the growth of the pharmaceutical excipients market in Europe. However, Asia-Pacific is predicted to grow at the high growth rate during the forecast period, owing to low cost of raw materials and availability of cost-effective workforce in this region. Moreover, the proliferation of pharmaceutical industry in countries like China, India and others is likely to offer immense opportunities for the growth of the market during the forecast period in terms of value sales.

Report Highlights

On the basis of product, the organic chemical segment holds the largest market share in the global market and is anticipated to retain its dominance during the forecast period.
On the basis of functionality, fillers & diluents segment holds the highest market share in the global market.
On the basis of formulation, oral formulation segment holds the largest market share in the global market and is anticipated to retain its dominance during the forecast period.
By region, Europe holds the largest market share in the global pharmaceutical excipients market. However, Asia-Pacific is expected to be the fastest growing market for the pharmaceutical excipients.

Table of Contents

Report Scope of the Pharmaceutical Excipients Market

Report Coverage	Details
Market Size in 2023	USD 8.37 Billion
Market Size by 2030	USD 12.61 Billion
Growth Rate from 2023 to 2030	CAGR of 5.9%
Largest Market	North America
Fastest Growing Market	Europe
Base Year	2022
Forecast Period	2023 to 2030
Segments Covered	Product, Functionality, Formulations, End-Users, Distribution Channel, Geography

Pharmaceutical Excipients Market Dynamics

Drivers

Growing requirement for biopharmaceuticals to augment market growth

Biopharmaceuticals are progressively becoming popular in the pharmaceutical industry owing to its similarity with the natural biological compound that is found in the body and have high potency and lesser side-effects. Thus, biopharmaceuticals form is one of the fastest growing segment in the pharmaceutical sector. Additionally, refinements in new concepts such as regenerative drugs are gradually being refined. This in turn is offering immense opportunity for the growth the market. Among the top 15 biopharmaceutical products, the most of the drugs currently available in the market are biopharmaceuticals. Hence, majority pharmaceutical firms across the globe are progressively shifting their R&D focus to macromolecule products.

Restrain

High priced& time-consuming drug development process to hamper the market growth

As per the California Biomedical Research Association (CBRA), a medicine takes on an average of 12 yrs to get from the lab to the patient, with toxicology studies taking 1–6 years. Furthermore, only 5 out of every 5,000 medications that begin preclinical research make it to human trials. Furthermore, late-stage failure in the medication development process raises R&D expenditures and reduce pharmaceutical company profit margins. Furthermore, tight rules on the protection & efficacy of pharmaceuticals, as well as raw materials including excipients, necessitate the improvement of current quality checks and production procedures, which increases the overall production cost. As a result, even if the medication development process has advanced significantly in recent years.

Opportunities

Proliferation of pharmaceutical industry in emerging economies

In recent years, the development of pharmaceuticals sector has been hampered owing to the government induced regulations on reducing healthcare costs and the mitigating medicine pipeline. This in turn has encouraged the pharmaceutical manufacturers to expand their manufacturing plants in the developing markets. The key players can take financial benefits including low-cost of production with regard to tax rates as well as lenient administrative guidelines.

Challenges

Safety and quality concerns

Recently changes in the government rules and regulations around the world, the prospective trade policies can present a challenge for the pharmaceutical sector and, therefore, for the pharmaceutical sector. Trade among the developing countries that are considered emerging countries such as China, India and Brazil and developed countries such as the United States as well as countries of European region, which are the main markets of the industry, could be severely affected. Important. The potential impact of the UK’s departure from the EU has prompted companies to consider moving – or shifting – their production from UK to France,Germany, and other European countries. While the impact of BREXIT on the pharmaceutical industry remains unclear, companies such as Astra Zeneca, Novartis, and Roche have relocated their production sites to reduce additional risks.

Key Market Developments

In 2020, Colorcon has launches the Acryl-EZE II film coating line which extends the pH range covered by its enteric coatings.
In 2019, Ashland has introduced Aquarius Nutra TF that provides titanium oxide-based coating to tablets in the European market.
In 2018, Roquette has signed an agreement with Thermo Fisher that provides Thermo the right to distribute Roquette’s products in the US and Canada. This will offer further market access to Roquette.

Pharmaceutical Excipients Market Companies

Ashland Global Holdings
BASF SE
DuPont
Roquette Feres
Evonik Industries AG
Associated British Foods
Archer Daniels Midland Company
Lubrizol Corporation
Croda International
Kerry Group

Market Segmentation:

By Product

Organic Chemicals
Inorganic Chemicals
Others

By Functionality

Fillers and Diluents
Suspending and Viscosity Agents
Coating Agents
Binders
Disintegrants
Colorants
Lubricants and Glidants
Preservatives
Emulsifying Agents
Flavoring Agents and Sweeteners
Other Functionalities

By Formulations

Topical Formulations
Oral Formulations
Parenteral Formulations
Other Formulations

By End-Users

Pharmaceuticals Companies
Research Organization
Academics
Others

By Distribution Channel

Online Pharmacy
Retail
Mail-Order

By Excipient Typeâ€‹

Lactose-based Excipients
- α-lactose monohydrate
- Anhydrous α-lactose
- Anhydrous β-lactoseâ€‹
- Amorphous Lactoseâ€‹
Cellulose-basedâ€‹
- Microcrystalline Cellulose (MCC)â€‹
- Cellulose Ethersâ€‹
- Othersâ€‹
Starchesâ€‹
Carboxymethylcellulose Sodium (CCS)â€‹
Sodium Starch Glycolate (SSG)â€‹
Fine Chemicalsâ€‹
Mannitol
Biopharma Excipientsâ€‹
Othersâ€‹

By Geography

North America
- U.S.
- Canada
Europe
- U.K.
- Germany
- France
Asia-Pacific
- China
- India
- Japan
- South Korea
- Malaysia
- Philippines
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC
- North Africa
- South Africa
- Rest of the Middle East & Africa